Vitae Pharmaceuticals (NASDAQ: VTAE) and Catalyst Biosciences (NASDAQ:CBIO) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.
Volatility & Risk
Vitae Pharmaceuticals has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Catalyst Biosciences has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500.
Insider & Institutional Ownership
72.6% of Vitae Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.6% of Catalyst Biosciences shares are owned by institutional investors. 14.8% of Vitae Pharmaceuticals shares are owned by company insiders. Comparatively, 5.0% of Catalyst Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Vitae Pharmaceuticals and Catalyst Biosciences’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Catalyst Biosciences||$561,999.00||25.85||-$19.79 million||($17.78)||-0.19|
Vitae Pharmaceuticals has higher revenue, but lower earnings than Catalyst Biosciences. Vitae Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalyst Biosciences, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings and target prices for Vitae Pharmaceuticals and Catalyst Biosciences, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Vitae Pharmaceuticals presently has a consensus price target of $21.67, suggesting a potential upside of 3.17%. Catalyst Biosciences has a consensus price target of $24.50, suggesting a potential upside of 618.48%. Given Catalyst Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Catalyst Biosciences is more favorable than Vitae Pharmaceuticals.
This table compares Vitae Pharmaceuticals and Catalyst Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Catalyst Biosciences beats Vitae Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
Vitae Pharmaceuticals Company Profile
Vitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer’s disease, or Alzheimer’s. VTP-43742, the Company’s wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.
What are top analysts saying about Vitae Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vitae Pharmaceuticals Inc and related companies.